AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

The company stock was down by over 22.7% in premarket trading as AN2 shared trial termination plans for epetraborole.

Aug 11, 2024 - 04:00

AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

The company stock was down by over 22.7% in premarket trading as AN2 shared trial termination plans for epetraborole.

Read the original article

Tags:

Previous Article

Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel...

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Opinion: Why we created a chatbot to help people at risk for eating disorders

Opinion: Why we created a chatbot to help people at ris...

Jun 10, 2023

Experts talk detecting disease from voice biomarkers with AI, privacy concerns

Experts talk detecting disease from voice biomarkers wi...

Nov 7, 2023

AbbVie to bolster neuroscience pipeline with Mitokinin acquisition

AbbVie to bolster neuroscience pipeline with Mitokinin ...

Oct 7, 2023